Join @RedChip for an investor Q&A webinar with ASP Isotopes (Nasdaq: ASPI) Executive Chairman and CEO Paul Mann, covering ASPI’s transition into commercial isotope production and its strategy at the intersection of clean energy, advanced semiconductors, and nuclear medicine.In our session, Paul addresses timelines for revenue-generating isotope shipments, updates on key facilities, capital position, and funding plans, as well as how ASPI’s partnerships could support long-term HALEU demand for next-generation nuclear reactors.ASP Isotopes is advancing proprietary isotope enrichment platforms supporting high-value end markets, including semiconductors (Silicon 28), nuclear medicine (including Yb-176 and other pipeline targets), and clean energy via HALEU supply initiatives. The company highlights definitive agreements with TerraPower for HALEU supply and financing, a joint venture with Fermi America for a U.S. enrichment presence, and a pending acquisition of Renergen to expand into helium and LNG.👉 ASP Isotopes is a client of RedChip. To learn more about ASPI and to read our full disclosure, visit: https://www.ASPIinfo.com #ASPI #Investing #SmallCapStocks #NuclearEnergy #HALEU #SMR #TerraPower #Semiconductors #Isotopes #QuantumComputing #NuclearMedicine #CleanEnergy #EnergyInvesting #TechInvesting